Pharmacogenetic Testing (PGT) is designed to detect genetic variations in enzymes associated with the metabolism of medications commonly prescribed to patients suffering from chronic pain and psychiatric disorders. Medication metabolism differs greatly among individuals and may partly be the result of genetic variations in metabolizing enzymes. These genetic variations can result in clinically significant differences in response to medications.

PGT will help more effectively personalize treatment by identifying patients who may benefit from modifying the drug selection or dosing of certain opioids, including codeine, hydrocodone, oxycodone, tramadol, and methadone; benzodiazepines; tricyclic antidepressants (TCAs); selective serotonin reuptake inhibitors (SSRIs); serotonin norepinephrine reuptake inhibitors (SNRIs); antipsychotics; muscle relaxants; atomoxetine.

• Assesses a number of key drug metabolism enzymes
• Identifies the underlying genetic characteristics that impact the metabolism of medications
• Simplifies specimen collection with a patient-friendly, noninvasive, saliva-based test
• May help predict a patient’s responses to medications
• Assists in clarifying a patient’s lower than expected clinical response
• May explain a patient’s higher than expected incidence of adverse effects

• Manage treatment strategy to maximize safety and efficacy
• Validate a patient’s urine drug testing (UDT) results
• Guide clinical decisions related to medication selection and dose

• Better individualize and inform choice of medications to treat pain and psychiatric disorders
• May reduce the need for excessive medication rotations
• Potentially avoid ineffective outcomes if rotating to a similarly metabolized medication